U.S. Markets closed

Eli Lilly and Company (LLY)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
201.26+2.78 (+1.40%)
At close: 4:00PM EST

201.26 +0.12 (0.06%)
After hours: 4:15PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close198.48
Open198.77
Bid201.40 x 800
Ask201.46 x 1300
Day's Range198.68 - 201.77
52 Week Range117.06 - 201.77
Volume4,923,049
Avg. Volume4,367,606
Market Cap192.522B
Beta (5Y Monthly)0.37
PE Ratio (TTM)32.93
EPS (TTM)6.11
Earnings DateJan 29, 2021
Forward Dividend & Yield3.40 (1.71%)
Ex-Dividend DateFeb 11, 2021
1y Target Est189.29
  • Barrons.com

    Eli Lilly Stock Is Surging on Hope for Alzheimer’s Drug. Analyst Says It Won’t Last.

    The company has said it will provide detailed data on the treatment on March 13. The stock is up some 19% over the past week.

  • Precision BioSciences' (DTIL) New Lymphoma Drug IND Gets FDA Nod
    Zacks

    Precision BioSciences' (DTIL) New Lymphoma Drug IND Gets FDA Nod

    The FDA accepts Precision BioSciences' (DTIL) regulatory application to initiate a clinical study on its next-generation CD19 product candidate, PBCAR19B.

  • MarketWatch

    Lilly signs cancer drug deal worth up to $1.6 billion

    Shares of Eli Lilly & Co. gained 0.8% in premarket trading on Wednesday, the day after the drugmaker announced a deal worth up to $1.6 billion with Merus to develop three antibody therapies aimed at treating cancer. The Dutch company's stock was down 5.1% in premarket trading on Wednesday. The deal, which includes research and a licensing agreement, is designed to give Merus an upfront payment of $40 million, a $20 million equity investment, and up to $540 million in potential milestone payments. Over the last year, Lilly's stock has gained 42.2%, shares of Merus are up 45.5%, and the S&P 500 has rallied 14.5%.